Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

Cozzi-Lepri, A.; Zangerle, R.; Machala, L.; Zilmer, K.; Ristola, M.; Pradier, C.; Kirk, O.; Sambatakou, H.; Fätkenheuer, G.; Yust, I.; Schmid, P.; Gottfredsson, M.; Khromova, I.; Jilich, D.; Flisiak, R.; Smidt, J.; Rozentale, B.; Radoi, R.; Losso, M.H.; Lundgren, J.D.; Mocroft, A.; Kundro, M.; Schmied, B.; Karpov, I.; Vassilenko, A.; Mitsura, V.M.; Paduto, D.; Clumeck, N.; De Wit, S.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Gerstoft, J.; Katzenstein, T.; Møller, N.F.; Pedersen, C.; Ostergaard, L.; Wiese, L.; Nielsen, L.N.; Aho, I.; Viard, J.-.; Girard, P.-.; Fontas, E.; Duvivier, C.; Rockstroh, J.; Schmidt, R.; Degen, O.; Stellbrink, H.J.; Stefan, C.; Bogner, J.; Chkhartishvili, N.; Gargalianos, P.; Xylomenos, G.; Lourida, P.; Szlávik, J.; Mulcahy, F.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Elbirt, D.; Sthoeger, Z.M.; D'Arminio Monforte, A.; Esposito, R.; Mazeu, I.; Mussini, C.; Mazzotta, F.; Gabbuti, A.; Vullo, V.; Lichtner, M.; Zaccarelli, M.; Antinori, A.; Acinapura, R.; Plazzi, M.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Uzdaviniene, V.; Matulionyte, R.; Staub, T.; Hemmer, R.; Reiss, P.; Ormaasen, V.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Horban, A.; Bakowska, E.; Grzeszczuk, A.; Parczewski, M.; Maciejewska, K.; Aksak-Was, B.; Beniowski, M.; Mularska, E.; Smiatacz, T.; Gensing, M.; Jablonowska, E.; Malolepsza, E.; Wojcik, K.; Mozer-Lisewska, I.; Caldeira, L.; Mansinho, K.; Maltez, F.; Oprea, C.; Panteleev, A.; Panteleev, O.; Yakovlev, A.; Trofimora, T.; Kuzovatova, E.; Borodulina, E.; Vdoushkina, E.; Jevtovic, D.; Tomazic, J.; Gatell, J.M.; Miró, J.M.; Moreno, S.; Rodriguez, J.M.; Clotet, B.; Jou, A.; Paredes, R.; Tural, C.; Puig, J.; Bravo, I.; Domingo, P.; Gutierrez, M.; Mateo, G.; Sambeat, M.A.; Laporte, J.M.; Falconer, K.; Thalme, A.; Sonnerborg, A.; Blaxhult, A.; Flamholc, L.; Scherrer, A.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Kuznetsova, A.; Kyselyova, G.; Sluzhynska, M.; Gazzard, B.; Johnson, A.M.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M.A.; Orkin, C.; Weber, J.; Scullard, G.; Clarke, A.; Leen, C.; Thiebaut, R.; Burger, D.; Peters, L.; Matthews, C.; Fischer, A.H.; Bojesen, A.; Raben, D.; Kristensen, D.; Grønborg Laut, K.; Larsen, J.F.; Podlekareva, D.; Shepherd, L.; Schultze, A.; Amele, S.

doi:10.1111/hiv.12557

Objectives: There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. Methods: The EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. Results: The RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95–1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37–2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84–1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90–1.61) and 0.83 (95% CI 0.70–0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47–1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65–1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53–1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76–1.72 for RALvs. CONC). Conclusions: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens / A. Cozzi-Lepri, R. Zangerle, L. Machala, K. Zilmer, M. Ristola, C. Pradier, O. Kirk, H. Sambatakou, G. Fätkenheuer, I. Yust, P. Schmid, M. Gottfredsson, I. Khromova, D. Jilich, R. Flisiak, J. Smidt, B. Rozentale, R. Radoi, M.H. Losso, J.D. Lundgren, A. Mocroft, M. Kundro, B. Schmied, I. Karpov, A. Vassilenko, V.M. Mitsura, D. Paduto, N. Clumeck, S. De Wit, M. Delforge, E. Florence, L. Vandekerckhove, V. Hadziosmanovic, J. Begovac, D. Sedlacek, G. Kronborg, T. Benfield, J. Gerstoft, T. Katzenstein, N.F. Møller, C. Pedersen, L. Ostergaard, L. Wiese, L.N. Nielsen, I. Aho, J.-. Viard, P.-. Girard, E. Fontas, C. Duvivier, J. Rockstroh, R. Schmidt, O. Degen, H.J. Stellbrink, C. Stefan, J. Bogner, N. Chkhartishvili, P. Gargalianos, G. Xylomenos, P. Lourida, J. Szlávik, F. Mulcahy, D. Turner, M. Burke, E. Shahar, G. Hassoun, H. Elinav, M. Haouzi, D. Elbirt, Z.M. Sthoeger, A. D'Arminio Monforte, R. Esposito, I. Mazeu, C. Mussini, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, M. Zaccarelli, A. Antinori, R. Acinapura, M. Plazzi, A. Lazzarin, A. Castagna, N. Gianotti, M. Galli, A. Ridolfo, V. Uzdaviniene, R. Matulionyte, T. Staub, R. Hemmer, P. Reiss, V. Ormaasen, A. Maeland, J. Bruun, B. Knysz, J. Gasiorowski, M. Inglot, A. Horban, E. Bakowska, A. Grzeszczuk, M. Parczewski, K. Maciejewska, B. Aksak-Was, M. Beniowski, E. Mularska, T. Smiatacz, M. Gensing, E. Jablonowska, E. Malolepsza, K. Wojcik, I. Mozer-Lisewska, L. Caldeira, K. Mansinho, F. Maltez, C. Oprea, A. Panteleev, O. Panteleev, A. Yakovlev, T. Trofimora, E. Kuzovatova, E. Borodulina, E. Vdoushkina, D. Jevtovic, J. Tomazic, J.M. Gatell, J.M. Miró, S. Moreno, J.M. Rodriguez, B. Clotet, A. Jou, R. Paredes, C. Tural, J. Puig, I. Bravo, P. Domingo, M. Gutierrez, G. Mateo, M.A. Sambeat, J.M. Laporte, K. Falconer, A. Thalme, A. Sonnerborg, A. Blaxhult, L. Flamholc, A. Scherrer, R. Weber, M. Cavassini, A. Calmy, H. Furrer, M. Battegay, A. Kuznetsova, G. Kyselyova, M. Sluzhynska, B. Gazzard, A.M. Johnson, E. Simons, S. Edwards, A. Phillips, M.A. Johnson, C. Orkin, J. Weber, G. Scullard, A. Clarke, C. Leen, R. Thiebaut, D. Burger, L. Peters, C. Matthews, A.H. Fischer, A. Bojesen, D. Raben, D. Kristensen, K. Grønborg Laut, J.F. Larsen, D. Podlekareva, L. Shepherd, A. Schultze, S. Amele. - In: HIV MEDICINE. - ISSN 1464-2662. - 19:2(2018 Feb), pp. 102-117.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

Cozzi-Lepri, A.;Zangerle, R.;Machala, L.;Zilmer, K.;Ristola, M.;Pradier, C.;Kirk, O.;Sambatakou, H.;Fätkenheuer, G.;Yust, I.;Schmid, P.;Gottfredsson, M.;Khromova, I.;Jilich, D.;Flisiak, R.;Smidt, J.;Rozentale, B.;Radoi, R.;Losso, M. H.;Lundgren, J. D.;Mocroft, A.;Kundro, M.;Schmied, B.;Karpov, I.;Vassilenko, A.;Mitsura, V. M.;Paduto, D.;Clumeck, N.;De Wit, S.;Delforge, M.;Florence, E.;Vandekerckhove, L.;Hadziosmanovic, V.;Begovac, J.;Sedlacek, D.;Kronborg, G.;Benfield, T.;Gerstoft, J.;Katzenstein, T.;Møller, N. F.;Pedersen, C.;Ostergaard, L.;Wiese, L.;Nielsen, L. N.;Aho, I.;Viard, J. -P.;Girard, P. -M.;Fontas, E.;Duvivier, C.;Rockstroh, J.;Schmidt, R.;Degen, O.;Stellbrink, H. J.;Stefan, C.;Bogner, J.;Chkhartishvili, N.;Gargalianos, P.;Xylomenos, G.;Lourida, P.;Szlávik, J.;Mulcahy, F.;Turner, D.;Burke, M.;Shahar, E.;Hassoun, G.;Elinav, H.;Haouzi, M.;Elbirt, D.;Sthoeger, Z. M.;A. D'Arminio Monforte^{Membro del Collaboration Group};Esposito, R.;Mazeu, I.;Mussini, C.;Mazzotta, F.;Gabbuti, A.;Vullo, V.;Lichtner, M.;Zaccarelli, M.;Antinori, A.;Acinapura, R.;Plazzi, M.;Lazzarin, A.;Castagna, A.;Gianotti, N.;M. Galli^{Membro del Collaboration Group};Ridolfo, A.;Uzdaviniene, V.;Matulionyte, R.;Staub, T.;Hemmer, R.;Reiss, P.;Ormaasen, V.;Maeland, A.;Bruun, J.;Knysz, B.;Gasiorowski, J.;Inglot, M.;Horban, A.;Bakowska, E.;Grzeszczuk, A.;Parczewski, M.;Maciejewska, K.;Aksak-Was, B.;Beniowski, M.;Mularska, E.;Smiatacz, T.;Gensing, M.;Jablonowska, E.;Malolepsza, E.;Wojcik, K.;Mozer-Lisewska, I.;Caldeira, L.;Mansinho, K.;Maltez, F.;Oprea, C.;Panteleev, A.;Panteleev, O.;Yakovlev, A.;Trofimora, T.;Kuzovatova, E.;Borodulina, E.;Vdoushkina, E.;Jevtovic, D.;Tomazic, J.;Gatell, J. M.;Miró, J. M.;Moreno, S.;Rodriguez, J. M.;Clotet, B.;Jou, A.;Paredes, R.;Tural, C.;Puig, J.;Bravo, I.;Domingo, P.;Gutierrez, M.;Mateo, G.;Sambeat, M. A.;Laporte, J. M.;Falconer, K.;Thalme, A.;Sonnerborg, A.;Blaxhult, A.;Flamholc, L.;Scherrer, A.;Weber, R.;Cavassini, M.;Calmy, A.;Furrer, H.;Battegay, M.;Kuznetsova, A.;Kyselyova, G.;Sluzhynska, M.;Gazzard, B.;Johnson, A. M.;Simons, E.;Edwards, S.;Phillips, A.;Johnson, M. A.;Orkin, C.;Weber, J.;Scullard, G.;Clarke, A.;Leen, C.;Thiebaut, R.;Burger, D.;Peters, L.;Matthews, C.;Fischer, A. H.;Bojesen, A.;Raben, D.;Kristensen, D.;Grønborg Laut, K.;Larsen, J. F.;Podlekareva, D.;Shepherd, L.;Schultze, A.;Amele, S.

2018

Abstract

Objectives: There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. Methods: The EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. Results: The RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95–1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37–2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84–1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90–1.61) and 0.83 (95% CI 0.70–0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47–1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65–1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53–1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76–1.72 for RALvs. CONC). Conclusions: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.

Scheda breve

Scheda completa

Scheda completa (DC)

	Parole chiave
	
			observational treatment comparison; propensity scores; Raltegravir; risk of cancer; survival; health policy; infectious diseases; pharmacology (medical)
		
	Settori scientifico-disciplinari dell'articolo
	
			Settore MED/17 - Malattie Infettive
Settore BIO/14 - Farmacologia
		
	Data di pubblicazione
	
			feb-2018
		
	Rivista in ANCE
	
			HIV MEDICINE
		
	DOI
	
			https://dx.doi.org/10.1111/hiv.12557
		
	Tipologia
	
			Article (author)
		
	Appare nelle tipologie:
	
			01 - Articolo su periodico

File in questo prodotto:

File	Dimensione	Formato
Cozzi-Lepri_et_al-2018-HIV_Medicine.pdf accesso aperto Tipologia: Publisher's version/PDF Dimensione 177.25 kB Formato Adobe PDF Visualizza/Apri	177.25 kB	Adobe PDF	Visualizza/Apri

Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/571934

Citazioni

2

7

7

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca